Mono- and bis-pyrazolophthalazines: Design, synthesis, cytotoxic activity, DNA/HSA binding and molecular docking studies

Bioorganic & Medicinal Chemistry
2021.0

Abstract

In an attempt to find new potent cytotoxic compounds, several mono- and bis-pyrazolophthalazines 4a-m and 6a-h were synthesized through an efficient, one-pot, three- and pseudo five-component synthetic approach. All derivatives were evaluated for their in vitro cytotoxic activities against four human cancer cell lines of A549, HepG2, MCF-7, and HT29. Compound 4e showed low toxicity against normal cell lines (MRC-5 and MCF 10A, IC > 200 µM) and excellent cytotoxic activity against A549 cell line with IC value of 1.25 ± 0.19 µM, which was 1.8 times more potent than doxorubicin (IC = 2.31 ± 0.13 µM). In addition, compound 6c exhibited remarkable cytotoxic activity against A549 and MCF-7 cell lines (IC = 1.35 ± 0.12 and 0.49 ± 0.01 µM, respectively), more than two-fold higher than that of doxorubicin. The binding properties of the best active mono- and bis-pyrazolophthalazine (4e and 6c) with HSA and DNA were fully evaluated by various techniques including UV-Vis absorption, circular dichroism (CD), Zeta potential and dynamic light scattering analyses indicating interaction of the compounds with the secondary structure of HSA and significant change of DNA conformation, presumably via a groove binding mechanism. Additionally, molecular docking and site-selective binding studies confirmed the fundamental interaction of compounds 4e and 6c with base pairs of DNA. Compounds 4e and 6c showed promising features to be considered as potential lead structures for further studies in cancer therapy.

Knowledge Graph

Similar Paper

Mono- and bis-pyrazolophthalazines: Design, synthesis, cytotoxic activity, DNA/HSA binding and molecular docking studies
Bioorganic & Medicinal Chemistry 2021.0
Synthesis and cytotoxic activity of a new potential DNA bisintercalator: 1,4-Bis{3-[N-(4-chlorobenzo[g]phthalazin-1-yl)aminopropyl]}piperazine
Bioorganic & Medicinal Chemistry 2010.0
Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation
European Journal of Medicinal Chemistry 2017.0
Synthesis and cytotoxicity evaluation of substituted pyridazino[4,5-b]phenazine-5,12-diones and tri/tetra-azabenzofluorene-5,6-diones
European Journal of Medicinal Chemistry 2007.0
Synthesis of pyrazolo[1,5-a]pyrimidine linked aminobenzothiazole conjugates as potential anticancer agents
Bioorganic & Medicinal Chemistry Letters 2013.0
Rational Design, Synthesis, and Biological Evaluation of Bis(pyrimido[5,6,1-de]acridines) and Bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as New Anticancer Agents
Journal of Medicinal Chemistry 2004.0
2,6-Di(ω-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones:  Novel, Potent, Cytotoxic, and DNA-Binding Agents
Journal of Medicinal Chemistry 2002.0
Synthesis of novel pyrazolo[3,4-d]pyrimidine derivatives as potential anti-breast cancer agents
European Journal of Medicinal Chemistry 2012.0
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds
Bioorganic & Medicinal Chemistry 2008.0
Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives
European Journal of Medicinal Chemistry 2014.0